Mastodawn

Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.
#YonhapInfomax #YuhanCorp #JohnsonAndJohnson #Leclaza #Rybrevant #NonSmallCellLungCancer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90019

Yuhan Corp. and Johnson & Johnson Launch Joint Domestic Promotion for 'Leclaza–Rybrevant' Combination Therapy

Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.

Yonhap Infomax

Scientific European Sep 1, 2024

First UK Lung Cancer Patient receives mRNA vaccine BNT116
BNT116 and LungVax are nucleic acid lung cancer vaccine candidates – the former is based on mRNA technology similar to “COVID-19 mRNA vaccines” such...........
#BNT116 #Cancer #DNAVaccine #Lungcancer #LungVax #mRNAVaccine #nonsmallcelllungcancer #NSCLC #UK #Vaccine
Umesh Prasad

https://www.scientificeuropean.co.uk/medicine/first-uk-lung-cancer-patient-receives-mrna-vaccine-bnt116/

First UK Lung Cancer Patient receives mRNA vaccine BNT116

BNT116 and LungVax are nucleic acid lung cancer vaccine candidates – the former is based on mRNA technology similar to “COVID-19 mRNA vaccines” such as BN

Scientific European